Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1441-1448

  Dreicer, Robert ^a   Garcia, Jorge ^a   Hussain, Maha ^b   Rini, Brian ^a   Vogelzang, Nicholas ^c   Srinivas, Sandy ^d   Somer, Bradley ^e   Zhao, Yan D ^f   Kania, Marek ^f   Raghavan, Derek ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e West Clinic   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Clinical trial; Enzastaurin; Prostate cancer; Prostate specific antigen

Indexed keywords

DOCETAXEL; ENZASTAURIN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; HYPONATREMIA; LOADING DRUG DOSE; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; URINARY FREQUENCY; URINARY URGENCY; VOMITING; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84856055618     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9428-0     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M (2009) Cancer Statistics, 2009. CA Cancer J Clin 59:225-249
2. D'Amico A, Whittington R, Malkowicz S et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281-286 (Pubitemid 34787593)
3. Moul J, Wu H, Sun L et al (2002) Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostatespecific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 132:213-219 (Pubitemid 35024764)
4. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. JNCI Cancer Spectrum 95:981-989 (Pubitemid 36896715)
5. Small EJ, Ryan C (2006) The case for secondary hormonal therapies in the chemotherapy age. J Urol 176:S66-S71 (Pubitemid 44648139)
6. Tannock I, de Wit R, Berry W et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512 (Pubitemid 39315317)
7. Pienta K, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665-1671
8. Knudsen K, Scher H (2009) Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15:4792-4798
9. Gescher A (2000) Staurosporine analogues-pharmacological toys or useful antitumour agents? Crit Rev Oncol Hematol 34:127-135 (Pubitemid 30229921)
10. Jarvis W, Grant S (1999) Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17:227-240 (Pubitemid 30037956)
11. Parker P, Murray-Rust J (2004) PKC at a glance. J Cell Sci 117:131-132 (Pubitemid 38128893)
12. Graff J, McNulty A, Hanna K et al (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469 (Pubitemid 41161281)
13. Koren R, Ben Meir D, Langzam L et al (2004) Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 11:321-326
14. Robertson M, Kahl B, Vose J et al (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25:1741-1746 (Pubitemid 46797955)
15. Carducci M, Musib L, Kies M et al (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099 (Pubitemid 46622284)
16. Petrylak DP, Sartor O, Witjes F et al (2007) A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). 2007 Prostate Cancer Symposium, Orlando Florida. Abstract 145
17. Sternberg C, Petrylak D, Sartor O et al (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27:5431-5438
18. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10 (Pubitemid 19099520)
19. Garhyan P, Baldwin J, Welch P, Thornton D (2009) Population pharmacokinetic modeling of enzastaurin and its major metabolite in healthy subjects and cancer patients. American Conference on Pharmacometrics 2009. http://www.go-acop.org/acop2009/posters. Accessed 07 Feb. 2010
20. Lawless JF (1982) Statistical models and methods for lifetime data (Wiley Series in Probability & Mathematical Statistics). Wiley, New York
21. Collett D (2003) Modelling survival data in medical research. Chapman & Hall/CRC, Boca Raton
22. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
23. Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925 (Pubitemid 46224110)
24. Dreicer R (2008) Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. Urol Oncol 26:426-429 (Pubitemid 351885379)
25. Podar K, Raab M, Chauhan D, Anderson K (2007) The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Invest Drug 16:1693-1707 (Pubitemid 350030716)
26. Deacon E, Pongracz J, Griffiths G, Lord J (1997) Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 50:124-131 (Pubitemid 27454996)
27. Ali A, Ali S, El-Rayes B, Philip P, Sarkar F (2009) Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 35:1-8